GB1442154A - Composition for promotion of protein synthesis and suppression of urea formation in the body - Google Patents
Composition for promotion of protein synthesis and suppression of urea formation in the bodyInfo
- Publication number
- GB1442154A GB1442154A GB3212173A GB3212173A GB1442154A GB 1442154 A GB1442154 A GB 1442154A GB 3212173 A GB3212173 A GB 3212173A GB 3212173 A GB3212173 A GB 3212173A GB 1442154 A GB1442154 A GB 1442154A
- Authority
- GB
- United Kingdom
- Prior art keywords
- keto
- analogues
- protein synthesis
- urea formation
- promotion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 239000004202 carbamide Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000001243 protein synthesis Methods 0.000 title abstract 2
- 230000014616 translation Effects 0.000 title abstract 2
- 230000001629 suppression Effects 0.000 title 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 3
- 229940024606 amino acid Drugs 0.000 abstract 3
- 235000001014 amino acid Nutrition 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 2
- 229960002885 histidine Drugs 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 159000000007 calcium salts Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 150000004715 keto acids Chemical class 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 abstract 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 abstract 1
- 229960004799 tryptophan Drugs 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Indole Compounds (AREA)
Abstract
1442154 Medicines comprising amino acid analogues M WALSER 5 July 1973 [30 April 1973] 32121/73 Heading A5B Pharmaceutical compositions for promoting protein synthesis and suppressing urea formation in the body, e.g. in renal failure, comprise a carrier and the a-keto analogues of valine, phenylalanine, methionine and leucine, the levo form of the a-keto analogue of isoleucine and either the amino acids histidine and tryptophan or their alpha-keto analogues. The alphaketo analogues of lysine, threonine and arginine and the amino acids L-tryptophan, L- threonine, L-lysine, and L-histidine or L- arginine may also be present. The keto acids may be in the form of their sodium or calcium salts and the compositions may be in forms suitable for oral and parenteral administration.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35532673A | 1973-04-30 | 1973-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1442154A true GB1442154A (en) | 1976-07-07 |
Family
ID=23397057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB3212173A Expired GB1442154A (en) | 1973-04-30 | 1973-07-05 | Composition for promotion of protein synthesis and suppression of urea formation in the body |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS49135966A (en) |
| BE (1) | BE803567A (en) |
| CA (1) | CA1023664A (en) |
| DE (1) | DE2335216A1 (en) |
| FR (1) | FR2226994B1 (en) |
| GB (1) | GB1442154A (en) |
| IL (1) | IL42787A (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3950529A (en) * | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| DE2530246A1 (en) * | 1975-07-07 | 1977-01-13 | Fresenius Chem Pharm Ind | L-AMINO ACID MIXTURES FOR PARENTERAL OR ORAL USE |
| DE2531299A1 (en) * | 1975-07-12 | 1977-01-13 | Fresenius Chem Pharm Ind | MIXTURES CONTAINING L-AMINO AND HYDROXY AND / OR KETO ACIDS FOR PARENTERAL OR ORAL USE |
| DE2636828A1 (en) * | 1976-08-16 | 1978-02-23 | Fresenius Chem Pharm Ind | (L)-Aminoacid mixt. for treating liver insufficiency - contains isoleucine, leucine, lysine, methionine and cysteine or cystine and non-essential aminoacid(s) |
| US4296127A (en) * | 1979-04-18 | 1981-10-20 | The Johns Hopkins University | Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof |
| US4752619A (en) * | 1985-12-23 | 1988-06-21 | The Johns Hopkins University | Nutritional supplement for treatment of uremia |
| SE8803143L (en) * | 1988-09-07 | 1990-03-08 | Kabivitrum Ab | ALTERNATIVE ENERGY SUBSTRATE |
| DE3943424A1 (en) * | 1989-12-30 | 1991-07-04 | Nephro Medica Pharma | Solns. for intravenous nutrition - contg. alpha-keto acids, for patients with kidney conditions, avoids nitrogen cpd. build-up |
| CA2831165A1 (en) * | 2011-04-18 | 2012-10-26 | Nestec S.A. | Nutritional compositions having .alpha.-hica and citrulline and methods of using same |
-
1973
- 1973-07-05 GB GB3212173A patent/GB1442154A/en not_active Expired
- 1973-07-11 DE DE19732335216 patent/DE2335216A1/en active Pending
- 1973-07-12 CA CA176,338A patent/CA1023664A/en not_active Expired
- 1973-07-19 IL IL42787A patent/IL42787A/en unknown
- 1973-08-03 FR FR7328498A patent/FR2226994B1/fr not_active Expired
- 1973-08-14 BE BE2052988A patent/BE803567A/en not_active IP Right Cessation
- 1973-10-11 JP JP48114328A patent/JPS49135966A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL42787A (en) | 1977-05-31 |
| IL42787A0 (en) | 1973-10-25 |
| AU6015373A (en) | 1975-03-13 |
| JPS49135966A (en) | 1974-12-27 |
| FR2226994A1 (en) | 1974-11-22 |
| FR2226994B1 (en) | 1977-08-12 |
| DE2335216A1 (en) | 1974-11-21 |
| BE803567A (en) | 1973-12-03 |
| CA1023664A (en) | 1978-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1511302A (en) | Pharmaceutical compositions comprising amino acid analogues | |
| US4499076A (en) | Elemental diets for liver diseases | |
| CA1212902A (en) | Amino acid solutions for parenteral nutrition and methods of formulation and use | |
| SE9402156L (en) | Pharmaceutical compositions containing the salts of s (+) - 2- (4-isobutylphenyl) propionic acid with basic amino acids | |
| GB1507951A (en) | Amino acid formulations | |
| US4434160A (en) | Nutrient solution for complete parenteral feeding and for increased energy production | |
| GB1399888A (en) | Injectable amino acid composition | |
| GB1442154A (en) | Composition for promotion of protein synthesis and suppression of urea formation in the body | |
| ATE84705T1 (en) | A FREE-FLOWING GRANULE CONTAINING IBUPROFEN AND A METHOD OF MANUFACTURE. | |
| BR9510168A (en) | Polyamino acid compound composition unit dosage form and method for preparing a composition | |
| TR199901132T2 (en) | To inhibit the release and/or synthesis of β-amyloid peptide using N-(aryl/heteoaryl) amino acid derivatives, pharmaceutical compositions containing them, and such compounds for methods. | |
| IE49586B1 (en) | Mixed salts of essential or semi-essential amino acids and nitrogen-free analogues thereof and their use in the treatment of renal and hepatic disorders | |
| SE8704217D0 (en) | AMINO ACID COMPOSITION FOR PARENTERAL NUTRITION | |
| CA2338533A1 (en) | Method of treating an autoimmune disorder | |
| GB1489447A (en) | Amino acid supplements | |
| NO883261D0 (en) | PROCEDURE FOR PREPARING A PHARMACEUTICAL PREPARATION | |
| JPH0463049B2 (en) | ||
| JPS568312A (en) | Amino acid pharmaceutical preparation | |
| GB1444621A (en) | Composition for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy-acid analogues of amino acids | |
| JP2534139B2 (en) | Oral amino acid preparation for renal failure | |
| GB1487334A (en) | Pharmaceutical preparations comprising lisuride and/or physiologically tolerable salts thereof | |
| GB1309150A (en) | Acthactive peptides and process for their manufacture | |
| WO1986002555A3 (en) | Amino acid solution-containing drug for the treatment of cancerous diseases and preparation process thereof | |
| Neuberger et al. | The availability of histidine derivatives for growth | |
| Dryden et al. | Vitamin B12 deficiency in the rat fed high protein rations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |